Medical/Pharmaceuticals

Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry part...

2025-10-15 23:05 2581

TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals.  CAMBRIDGE, Mass., Oct. 15, 2025 /PRNewswire/ -- TriNetX, driven by its vision of a connected world where data and intelligence powe...

2025-10-15 20:34 1515

SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia

* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...

2025-10-15 20:00 2090

Tamarind Health Marks Next Phase as Asia's Leading Integrated Oncology Platform

SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- Tamarind Health marks the next phase in its growth asAsia's leading integrated oncology-focused healthcare platform, following the completion of its acquisition of TalkMED inSeptember 2025. A doctor-led platform built on the principle of putting patients f...

2025-10-15 17:01 1146

Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD

VIENNA, Oct. 15, 2025 /PRNewswire/ -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrati...

2025-10-15 14:34 1476

Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals

Safex earns global recognition for its innovation-driven strategy, digital transformation, and customer-centric approach in the evolving crop protection chemicals industry. SAN ANTONIO, Oct. 15, 2025 /PRNewswire/ -- Frost & Sullivan

2025-10-15 14:00 1156

At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality

SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions now affect more than 40% of the population—over 3 billion people, according to WHO's Global Status Report on Neurology, released at the World Congress of Neurology (WCN) inSeoul. The report reveals that neurolog...

2025-10-15 13:32 1033

Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth

CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based inShangh...

2025-10-15 08:00 1332

Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the E...

2025-10-15 00:00 2634

Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...

2025-10-14 21:03 2676

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnos...

2025-10-14 21:00 1159

Pictor's Proteomics Platform Offers Promising Advancement for Detecting Mycoplasma bovis in Cattle

New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management.  CARLSBAD, Calif., Oct. 14, 2025 /PRNewswire/ -- Mycoplasma bovis is a devastating pathogen that threate...

2025-10-14 21:00 1004

India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...

2025-10-14 20:30 1368

Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"

—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing,Zhejiang, bringing together a prestigious gathering of leading minds in ...

2025-10-14 20:30 1525

India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...

2025-10-14 20:30 1163

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...

2025-10-14 20:00 1826

Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...

2025-10-14 18:18 1550

Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation di...

2025-10-14 18:02 1135

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...

2025-10-14 18:00 1495

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...

2025-10-14 14:59 1590
1 ... 44454647484950 ... 644

Week's Top Stories